Migraines remidies
Reading File
Finding Sources
Searching PubMed
migraine treatment management
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Here is a comprehensive overview of migraine remedies, drawing from multiple authoritative sources:
Migraine Remedies
π΅ Acute (Abortive) Treatment
The goal is to treat as early as possible β during the aura or at the very onset of headache.
1. Mild-to-Moderate Attacks β First-Line
- NSAIDs (aspirin, ibuprofen, naproxen, ketorolac): First-line for mild attacks. Try 2β3 different NSAIDs across attacks if one fails. High doses may be needed.
- Acetaminophen: Can be adequate for milder headaches.
- Antiemetics: Used alongside analgesics to control nausea/vomiting:
- Prochlorperazine 5β10 mg IV/PR
- Metoclopramide 10 mg IV
- Droperidol 2.5 mg IV
β οΈ Overusing NSAIDs can trigger medication overuse (rebound) headache β a cycle of relief followed by worsened headache.
2. Moderate-to-Severe Attacks β Triptans (First-Line Specific Therapy)
Triptans are 5-HT1B/1D receptor agonists that abort migraine in ~70% of patients. They cause cranial vasoconstriction and inhibit trigeminal neuropeptide release.
| Triptan | Route | Usual Dose |
|---|---|---|
| Sumatriptan | SC / Nasal / Oral | 6 mg SC; 20 mg nasal; 50β100 mg oral |
| Rizatriptan | Oral | 5β10 mg |
| Zolmitriptan | Oral / Nasal | 2.5β5 mg |
| Eletriptan | Oral | 20β40 mg |
| Almotriptan | Oral | 12.5 mg |
| Frovatriptan | Oral | 2.5 mg (longest-acting, tΒ½ >24 h) |
| Naratriptan | Oral | 2.5 mg |
- Subcutaneous onset: ~20 min; oral: 1β2 h
- Headache may recur in 24β48 h; a second dose is usually effective
- If one triptan fails, try another β individual response varies
Contraindications: Coronary artery disease, uncontrolled hypertension, basilar/hemiplegic migraine
3. Ergot Alkaloids
- Dihydroergotamine (DHE) 1 mg IV/IM or intranasal β effective for severe migraine; often used in ED settings; pretreat with antiemetic
- Ergotamine tartrate 1β2 mg sublingual or oral (Β± caffeine) β largely replaced by triptans due to vasoconstriction side effects and rebound risk
Contraindications: Ischemic heart disease, peripheral vascular disease, pregnancy, uncontrolled HTN, recent triptan use (within 24 h)
4. Newer Agents
- Gepants (CGRP receptor antagonists) β e.g., ubrogepant, rimegepant: useful for those who cannot tolerate or don't respond to triptans; about 20% achieve pain freedom
- Ditans (5-HT1F agonists) β e.g., lasmiditan: act on the trigeminal system without vasoconstriction; an option for patients with cardiovascular contraindications to triptans
5. Emergency / Rescue Options
- Magnesium sulfate 2 g IV over 30 min
- Dexamethasone 6β10 mg IV (adjunctive; reduces recurrence)
- Valproate 500 mg IV
- Ketamine 0.1β0.3 mg/kg IV (useful if head trauma present)
π’ Preventive (Prophylactic) Treatment
Indicated when attacks are frequent (typically >1 severe episode/week) or severe enough to impair function. Comorbidities should guide drug choice.
| Drug Class | Agents | Notes |
|---|---|---|
| Beta-blockers | Propranolol 80β240 mg/d; atenolol; metoprolol; timolol | First-line; prefer those without intrinsic agonist activity |
| Antiepileptics | Valproate 250 mg 3β4Γ/d; topiramate | Avoid valproate in pregnancy |
| Tricyclic antidepressants | Amitriptyline 25β125 mg nightly | May be preferred if headaches are very frequent |
| Calcium channel blockers | Verapamil 320β480 mg/d | Useful if other agents fail |
| CGRP monoclonal antibodies | Erenumab, fremanezumab, galcanezumab | Newer class; demonstrated efficacy in chronic migraine |
| Botulinum toxin (Botox) | Injected into temporalis/cranial muscles | 2β4 months of relief; approved for chronic migraine |
| Occipital nerve block | Greater occipital nerve injection | Adjunctive option |
π‘ Lifestyle & Non-Pharmacological Approaches
- Dietary triggers to avoid: Chocolate, red wine, smoked meats, peanuts, aged cheeses, hot dogs, oranges
- Caffeine: Limit intake; caffeine can potentiate analgesics but also cause rebound
- Sleep regularity and stress management are important
- Biofeedback and cognitive behavioral therapy: supported by some trials
- Acupuncture: evidence modest but not negligible
- Correct refractive errors if present
- Perimenstrual migraine: consider indomethacin or frovatriptan as preventive therapy around the cycle
Recent Guidelines (2025)
Two landmark practice guidelines published in Cephalalgia (April 2025) by Ornello et al. provide updated evidence-based recommendations for pharmacological migraine treatment:
- Evidence-based guidelines for pharmacological treatment of migraine (PMID 40277319)
- A 2024 BMJ network meta-analysis (PMID 39293828) compared all available acute migraine drugs across 53+ trials and found modest but meaningful differences between agents β reinforcing triptan superiority for most patients.
Sources: Adams and Victor's Principles of Neurology 12th Ed.; Lippincott Illustrated Reviews: Pharmacology; Tintinalli's Emergency Medicine; Goodman & Gilman's Pharmacological Basis of Therapeutics
This is a shared conversation. Sign in to Orris to start your own chat.